Developmental Funds provide critical support to build research capacity aligned with strategic initiatives. Funds are requested to partially support two key initiatives: 1) recruitment of outstanding investigators to Huntsman Cancer Institute (HCI) ($200,000 per year) and 2) development of our translational research portfolio ($100,000 per year), via the following: Faculty Recruitment: Our five research Programs continue to identify areas of particular opportunity that align with the broad strategic objectives of the Cancer Center. We anticipate that the Cancer Center will spearhead recruitment of approximately 30 new members in the coming five-year period, with particular focus on high-priority areas that have emerged from our strategic planning. These include cancer genetics and epigenetics, cell migration and tumor metastasis, molecular imaging, investigational therapeutics, cancer prevention, epidemiology, behavioral research, and cancer outcomes, including research related to health disparities and survivorship. New recruitment will advance the missions of each of our Programs, with the greatest growth anticipated in our two newest Programs Imaging, Diagnostics, and Therapeutics and Cancer Control and Population Sciences with at least five recruits each. In addition, a major commitment is in place to recruit new leadership for the Divisions of Hematology and Oncology and to expand both Divisions via recruitment of cancer-focused, research-active faculty whose interests align with the abovementioned Cancer Center goals. We plan 14 new cancer-focused faculty recruitments in partnership with these two units during the next five years. These new faculty will be aligned with Cancer Center Programs based on their research interests. We request developmental funds in the amount of $200,000 per year to provide partial support ($50,000 per person) for four newly recruited investigators per year during their initial startup period. Translational Research: We have developed an effective strategy to promote translational research in our Center through the Director's Translational Research Initiative (DTRI). This initiative provides support for promising collaborative projects between basic scientists (including laboratory and population researchers) and clinical investigators. The goal is to stimulate productive transdisciplinary research with near-term clinical application. We request $100,000 per year for the partial support of this mechanism. Total annual support requested from the CCSG for developmental activities is $300,000. This amount will be complemented by HCI discretionary funds and other institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-23
Application #
8378924
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$204,800
Indirect Cost
$22,185
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Warner, Echo L; Ding, Qian; Pappas, Lisa et al. (2017) Health Care Providers' Knowledge of HPV Vaccination, Barriers, and Strategies in a State With Low HPV Vaccine Receipt: Mixed-Methods Study. JMIR Cancer 3:e12
Affolter, Kajsa; Gligorich, Keith; Samadder, Niloy Jewel et al. (2017) Feasibility of Large-Scale Identification of Sessile Serrated Polyp Patients Using Electronic Records: A Utah Study. Dig Dis Sci 62:1455-1463
Fowler, Brynn; Samadder, N Jewel; Kepka, Deanna et al. (2017) Improvements in Colorectal Cancer Incidence Not Experienced by Nonmetropolitan Women: A Population-Based Study From Utah. J Rural Health :
Ou, Judy Y; Smits-Seemann, Rochelle R; Kaul, Sapna et al. (2017) Risk of hospitalization among survivors of childhood and adolescent acute lymphoblastic leukemia compared to siblings and a general population sample. Cancer Epidemiol 49:216-224
VanderLinden, Ryan T; Hemmis, Casey W; Yao, Tingting et al. (2017) Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism. J Biol Chem 292:9493-9504
Cohen, Adam L; Factor, Rachel E; Mooney, Kathi et al. (2017) POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast 31:219-223
Gardiner, Jamie D; Abegglen, Lisa M; Huang, Xiaomeng et al. (2017) C/EBP?-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Oncotarget 8:26013-26026
Ding, Yun; Fleming, Aaron M; Burrows, Cynthia J (2017) Sequencing the Mouse Genome for the Oxidatively Modified Base 8-Oxo-7,8-dihydroguanine by OG-Seq. J Am Chem Soc 139:2569-2572
Carleton, Julia B; Berrett, Kristofer C; Gertz, Jason (2017) Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor ?-Bound Enhancers. Cell Syst 5:333-344.e5
Lai, Run-Zhi; Han, Xue-Sheng; Dahlquist, Frederick W et al. (2017) Paradoxical enhancement of chemoreceptor detection sensitivity by a sensory adaptation enzyme. Proc Natl Acad Sci U S A 114:E7583-E7591

Showing the most recent 10 out of 1113 publications